



Can Fondaparinux be used for Thromboprophylaxis in hospitalized covid patients

- British Journal OF Hematology suggests that all hospitalized COVID-19 patients should receive thromboprophylaxis, or full therapeutic-intensity anticoagulation if such an indication is present⁽¹⁾ .
- Fondaparinux has shown to be associated with lesser incidence of DVT and PE and larger decline in CRP levels as compared to Enoxaparin^(2,3).
- Further, due to lower molecular weight and lesser saccharide residues, Fondaparinux is associated with minimum HIT risk as compared to Enoxaparin⁽⁴⁾.

References:

1. Anastasios Kollias British Journal of Haematology 2020 189 846-847
2. Vincenzo Russo, J Cardiovasc Pharmacol 2020;76:369–371,
3. Cardillo et al, Journal of Blood Medicine 2021:12 69–75